In today’s recent session, 0.49 million shares of the TransCode Therapeutics Inc (NASDAQ:RNAZ) have been traded, and its beta is 0.63. Most recently the company’s share price was $0.59, and it changed around $0.0 or 0.27% from the last close, which brings the market valuation of the company to $10.17M. RNAZ at last check was trading at a discount to its 52-week high of $19.42, offering almost -3191.53% off that amount. The share price’s 52-week low was $0.22, which indicates that the recent value has risen by an impressive 62.71% since then. We note from TransCode Therapeutics Inc’s average daily trading volume that its 10-day average is 0.88 million shares, with the 3-month average coming to 2.02 million.
TransCode Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended RNAZ as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. TransCode Therapeutics Inc is expected to report earnings per share of -0.49 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TransCode Therapeutics Inc (NASDAQ:RNAZ) trade information
Instantly RNAZ has been showing a green trend so far today with a performance of 0.27% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.7700 on recent trading dayincreased the stock’s daily price by 23.38%. The company’s shares are currently down -91.06% year-to-date, but still down -4.21% over the last five days. On the other hand, TransCode Therapeutics Inc (NASDAQ:RNAZ) is -8.55% down in the 30-day period. We can see from the shorts that 1.22 million shares have been sold at a short interest cover period of 0.38 day(s).
TransCode Therapeutics Inc (RNAZ) estimates and forecasts
TransCode Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 0.36 percent over the past six months and at a 98.01% annual growth rate that is well above the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 99.30% in revenue this quarter, and will report an increase of 99.20% in the next quarter.
Consensus estimates provided by 1 financial analysts predict the company will bring in an average of 300k in revenue for the current quarter. 1 analysts expect TransCode Therapeutics Inc to make 300k in revenue for the current ending quarter.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -28.81%.
RNAZ Dividends
TransCode Therapeutics Inc’s next quarterly earnings report is expected to be released on 2024-Aug-14.
TransCode Therapeutics Inc (NASDAQ:RNAZ)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.03% of TransCode Therapeutics Inc shares, and 11.46% of them are in the hands of institutional investors. The stock currently has a share float of 11.47%.
